Bill Text: NY S00660 | 2015-2016 | General Assembly | Introduced


Bill Title: Requires disclosure of addiction risks for certain prescription drugs; requires physicians, nurses and pharmacists to provide information on prevention, mitigation and treatment of prescription drug addiction and to have the patient sign a form acknowledging education of such risks.

Spectrum: Partisan Bill (Democrat 4-0)

Status: (Introduced - Dead) 2016-01-06 - REFERRED TO HEALTH [S00660 Detail]

Download: New_York-2015-S00660-Introduced.html
                           S T A T E   O F   N E W   Y O R K
       ________________________________________________________________________
                                          660
                              2015-2016 Regular Sessions
                                   I N  S E N A T E
                                      (PREFILED)
                                    January 7, 2015
                                      ___________
       Introduced  by  Sens. KENNEDY, AVELLA, HASSELL-THOMPSON, KRUEGER -- read
         twice and ordered printed, and when printed to  be  committed  to  the
         Committee on Health
       AN  ACT  to  amend  the public health law and the mental hygiene law, in
         relation to  requiring  disclosure  of  addiction  risks  for  certain
         prescription drugs
         THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
       BLY, DO ENACT AS FOLLOWS:
    1    Section 1. This act shall be known and may be cited  as  the  "Michael
    2  David Israel patient information act".
    3    S 2.  The public health law is amended by adding a new section 3317 to
    4  read as follows:
    5    S  3317.    REQUIRED DISCLOSURES. 1. DEFINITIONS. FOR PURPOSES OF THIS
    6  SECTION:
    7    (A) "OPIATE ANALGESICS" SHALL MEAN THE MEDICINES BUPRENORPHINE, BUTOR-
    8  PHANOL, CODEINE, HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,  MEPERIDINE,
    9  METHADONE, MORPHINE, NALBUPHINE, OXYCODONE, OXYMORPHONE, PENTAZOCINE AND
   10  PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
   11    (B)  "PSYCHOTROPIC DRUGS" SHALL MEAN ANY DRUG OR MEDICINE THAT AFFECTS
   12  MENTAL ACTIVITY, BEHAVIOR OR PERCEPTION INCLUDING ANTI-PSYCHOTICS, ANTI-
   13  DEPRESSANTS, ANTI-ANXIETY DRUGS OR ANXIOLYTICS AND HYPNOTICS.
   14    2. DISCLOSURES. WHENEVER A PRACTITIONER, PHARMACIST, REGISTERED  NURSE
   15  OR ANY OTHER PERSON WHO IS AUTHORIZED TO DISTRIBUTE SUBSTANCES REGULATED
   16  BY  THIS ARTICLE, DISPENSES OPIATE ANALGESICS OR PSYCHOTROPIC DRUGS SUCH
   17  PRESCRIBING PHYSICIAN, NURSE OR PHARMACIST SHALL:
   18    (A) DESCRIBE THE RISKS OF ADDICTION TO THE PATIENT;
   19    (B) AFTER CONSULTING THE PATIENT'S MEDICAL HISTORY, INFORM THE PATIENT
   20  OF HIS OR HER CHANCE OF ADDICTION;
        EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                             [ ] is old law to be omitted.
                                                                  LBD03249-01-5
       S. 660                              2
    1    (C) PROVIDE THE PATIENT WITH  INFORMATION  ABOUT  COPING  WITH  OPIATE
    2  ANALGESIC  OR  PYSCHOTROPIC DRUG ADDICTION AND AVAILABLE LOCAL RESOURCES
    3  INCLUDING DETOXIFICATION CENTERS, COUNSELING SERVICES AND HOTLINES; AND
    4    (D)  HAVE  THE PATIENT SIGN A FORM APPROVED BY THE DEPARTMENT ACKNOWL-
    5  EDGING THAT HE OR SHE HAS BEEN INFORMED OF  THE  PREVENTION,  MITIGATION
    6  AND TREATMENT OF SUCH ADDICTION.
    7    3.  ENFORCEMENT BY DEPARTMENT. (A) THE DEPARTMENT SHALL BE RESPONSIBLE
    8  FOR PUBLISHING INFORMATIONAL PAMPHLETS REGARDING THE DANGERS  OF  OPIATE
    9  ANALGESICS AND PSYCHOTROPIC DRUGS AND DISTRIBUTION. SUCH PAMPHLETS SHALL
   10  TAKE  THE FORM PRESCRIBED BY THE COMMISSIONER. THE DEPARTMENT SHALL ALSO
   11  PROVIDE THE FORM REQUIRED IN PARAGRAPH (D) OF SUBDIVISION  TWO  OF  THIS
   12  SECTION.
   13    (B) THE DEPARTMENT SHALL BE RESPONSIBLE FOR THE RECEIPT, INVESTIGATION
   14  AND SUBSTANTIATION OF ANY COMPLAINTS OR TIPS ABOUT PHYSICIANS, NURSES OR
   15  PHARMACISTS  WHO  FAIL  TO  PROVIDE  THE  INFORMATION  MANDATED  IN THIS
   16  SECTION. FAILURE TO PROVIDE SUCH  INFORMATION  SHALL  BE  PUNISHABLE  AS
   17  FOLLOWS:
   18    (I) FIRST OFFENSE; FINE OF UP TO ONE THOUSAND DOLLARS;
   19    (II) SECOND OFFENSE: FINE OF UP TO FIVE THOUSAND DOLLARS;
   20    (III) THIRD OFFENSE: SUSPENSION OF LICENSE UP TO SIX MONTHS;
   21    (IV) FOURTH OFFENSE: SUSPENSION OF LICENSE UP TO ONE YEAR;
   22    (V)  FIFTH  OFFENSE: PERMANENT SUSPENSION OR REVOCATION OF LICENSE AND
   23  REFERRED TO THE RESPECTIVE LICENSING BOARDS UNDER THIS ARTICLE.
   24    A SIGNED PATIENT FORM SHALL BE  PRIMA  FACIE  PROOF  THAT  THE  PERSON
   25  PRESCRIBING  SUCH  MEDICATIONS  HAS COMPLIED WITH THE PROVISIONS OF THIS
   26  SECTION.
   27    S 3. The mental hygiene law is amended by adding a new section 19.18-b
   28  to read as follows:
   29  S 19.18-B REQUIRED DISCLOSURES.
   30    (A) DEFINITIONS. FOR PURPOSES OF THIS SECTION:
   31    (1) "DEPARTMENT" SHALL MEAN THE DEPARTMENT OF HEALTH.
   32    (2) "OPIATE ANALGESICS" SHALL MEAN THE MEDICINES BUPRENORPHINE, BUTOR-
   33  PHANOL, CODEINE, HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,  MEPERIDINE,
   34  METHADONE, MORPHINE, NALBUPHINE, OXYCODONE, OXYMORPHONE, PENTAZOCINE AND
   35  PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
   36    (3)  "PSYCHOTROPIC DRUGS" SHALL MEAN ANY DRUG OR MEDICINE THAT AFFECTS
   37  MENTAL ACTIVITY, BEHAVIOR OR PERCEPTION INCLUDING ANTI-PSYCHOTICS, ANTI-
   38  DEPRESSANTS, ANTI-ANXIETY DRUGS OR ANXIOLYTICS AND HYPNOTICS.
   39    (B) DISCLOSURES. WHENEVER A PRACTITIONER, PHARMACIST, REGISTERED NURSE
   40  OR ANY OTHER PERSON WHO IS AUTHORIZED TO DISTRIBUTE SUBSTANCES REGULATED
   41  BY THIS ARTICLE OR THOSE REGULATED UNDER  ARTICLE  THIRTY-THREE  OF  THE
   42  PUBLIC  HEALTH  LAW,  DISPENSES OPIATE ANALGESICS OR PSYCHOTROPIC DRUGS,
   43  SUCH PRESCRIBING PHYSICIAN, NURSE OR PHARMACIST SHALL:
   44    (1) DESCRIBE THE RISKS OF ADDICTION TO THE PATIENT;
   45    (2) AFTER CONSULTING THE PATIENT'S MENTAL HISTORY, INFORM THE  PATIENT
   46  OF HIS OR HER CHANCE OF ADDICTION;
   47    (3)  PROVIDE  THE  PATIENT  WITH  INFORMATION ABOUT COPING WITH OPIATE
   48  ANALGESIC OR PSYCHOTROPIC DRUG ADDICTION AND AVAILABLE  LOCAL  RESOURCES
   49  INCLUDING DETOXIFICATION CENTERS, COUNSELING SERVICES AND HOTLINES; AND
   50    (4)  HAVE  THE PATIENT SIGN A FORM APPROVED BY THE DEPARTMENT ACKNOWL-
   51  EDGING THAT HE OR SHE HAS BEEN INFORMED OF  THE  PREVENTION,  MITIGATION
   52  AND TREATMENT OF SUCH ADDICTION.
   53    (C) ENFORCEMENT BY DEPARTMENT. (1) THE DEPARTMENT SHALL BE RESPONSIBLE
   54  FOR  PUBLISHING  INFORMATIONAL PAMPHLETS REGARDING THE DANGERS OF OPIATE
   55  ANALGESICS AND PSYCHOTROPIC DRUGS FOR DISTRIBUTION. SUCH PAMPHLETS SHALL
   56  TAKE THE FORM PRESCRIBED BY THE COMMISSIONER OF HEALTH.  THE  DEPARTMENT
       S. 660                              3
    1  SHALL  ALSO  PROVIDE  THE FORM REQUIRED IN PARAGRAPH FOUR OF SUBDIVISION
    2  (B) OF THIS SECTION.
    3    (2) THE DEPARTMENT SHALL BE RESPONSIBLE FOR THE RECEIPT, INVESTIGATION
    4  AND SUBSTANTIATION OF ANY COMPLAINTS OR TIPS ABOUT PHYSICIANS, NURSES OR
    5  PHARMACISTS  WHO  FAIL  TO  PROVIDE  THE  INFORMATION  MANDATED  IN THIS
    6  SECTION. FAILURE TO PROVIDE SUCH  INFORMATION  SHALL  BE  PUNISHABLE  AS
    7  FOLLOWS:
    8    (I) FIRST OFFENSE: FINE OF UP TO ONE THOUSAND DOLLARS;
    9    (II) SECOND OFFENSE: FINE OF UP TO FIVE THOUSAND DOLLARS;
   10    (III) THIRD OFFENSE: SUSPENSION OF LICENSE UP TO SIX MONTHS;
   11    (IV) FOURTH OFFENSE: SUSPENSION OF LICENSE UP TO ONE YEAR;
   12    (V)  FIFTH  OFFENSE: PERMANENT SUSPENSION OR REVOCATION OF LICENSE AND
   13  REFERRED TO THE RESPECTIVE LICENSING BOARDS UNDER  ARTICLE  THIRTY-THREE
   14  OF THE PUBLIC HEALTH LAW.
   15    A  SIGNED  PATIENT  FORM  SHALL  BE  PRIMA FACIE PROOF THAT THE PERSON
   16  PRESCRIBING SUCH MEDICATIONS HAS COMPLIED WITH THE  PROVISIONS  OF  THIS
   17  SECTION.
   18    S 4. This act shall take effect immediately.
feedback